What happened with PHAT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Phathom Pharmaceuticals sells prescription medicines containing vonoprazan, which reduces stomach acid. VOQUEZNA tablets generate most of its revenue, and most prescriptions are for gastroesophageal reflux disease (GERD). For H. pylori infection, it also sells VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK, which package vonoprazan with antibiotics. All revenue comes from U.S. sales, with a small group of wholesale distributor and retailer customers accounting for most sales.
Demand depends on doctors prescribing the medicines and patients being able to afford them through private insurance, government coverage or out-of-pocket payments. For GERD, insurers commonly require patients to try a cheaper generic acid-suppressing medicine before covering VOQUEZNA. Phathom can promote its products only for their approved uses, which are specified adult conditions.
Phathom licenses its vonoprazan rights from Takeda and pays royalties on sales. Keeping that license is essential to continuing the business; it also generally bars Phathom from commercializing competing medicines for acid-related disorders, subject to limited exceptions. Phathom has no manufacturing facilities and relies on Evonik and Catalent for vonoprazan production and on Sandoz for antibiotics and the finished treatment packs.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Phathom’s results hinge chiefly on VOQUEZNA’s uptake against inexpensive generic proton pump inhibitors for GERD, with Sebela Pharmaceuticals’ tegoprazan a potential direct PCAB rival.
Phathom’s entire commercial portfolio depends on vonoprazan patents and know-how licensed from Takeda, which receives royalties on Phathom’s sales. Those payments link Takeda directly to U.S. sales of VOQUEZNA tablets, DUAL PAK and TRIPLE PAK.
RedHill Biopharma competes for the same U.S. adult H. pylori treatment sales as Phathom’s VOQUEZNA DUAL PAK and TRIPLE PAK through Talicia, a capsule combining omeprazole and two antibiotics. Watch Talicia’s U.S. sales for the competitive pressure on Phathom’s two PAK products, rather than its GERD tablets.
Phathom Pharmaceuticals, Inc. earningsThis company
Phathom Pharmaceuticals relies on U.S. VOQUEZNA sales, and this report will show whether prescription growth is keeping pace with the costs of selling and developing its products.
Read net product revenue alongside operating expenses. Revenue growing faster than expenses would show that prescriptions are bringing in more money to support commercialization and research; slowing revenue or persistently high expenses would show sales have not yet covered the business’s spending, leaving Phathom more reliant on cash and financing.
Takeda Pharmaceutical Company Limited earningsTAK
Takeda’s report will show royalty income from licensed products, a revenue stream linked to Phathom Pharmaceuticals’ U.S. VOQUEZNA sales.
Look at Takeda’s royalty income and what it says is driving it. Higher royalties indicate growing income from licensed-product sales, a link to Phathom’s VOQUEZNA business, but do not prove Phathom’s sales increased; lower royalties could reflect weaker sales of licensed products or other factors, not necessarily a decline at Phathom. The report is a read-through, not a measure of Phathom’s own results.
